Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs

British Journal of Cancer

Volumn 99, Issue 3, 2008, Pages 473-480

  Gelardi, T ^a   Caputo, R ^a   Damiano, V ^a   Daniele, G ^a   Pepe, S ^a   Ciardiello, F ^b   Lahn, M ^c   Bianco, R ^a   Tortora, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Drug resistance; EGFR inhibitors; Targeted therapy

Indexed keywords

CETUXIMAB; ENZASTAURIN; GEFITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INDOLES; MICE; MICE, NUDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 48349117187     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604493     Document Type: Article

References (35)

1. Aeder SE, Martin PM, Soh JW, Hussaini IM (2004) PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene 23: 9062-9069
2. Beerepoot L, Rademaker-Lakhai J, Witteveen E, Radema S, Viseren-Grul C, Musib L, Van Hal J, Beijnen J, Schellens J, Voest E (2007) Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer. Clin Cancer Res 13: 4474-4481
3. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812-2822
4. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS (2006) Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24: 4092-4099
5. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
6. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G (2004) Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10: 784-793
7. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G (2000) Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6: 3739-3747
8. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465
9. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G (1996) Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 88: 1770-1776
10. Ciardiello F, Tortora G (2008) Epidermal growth factor receptor (EGFR) antagonists in cancer treatment. N Engl J Med 358: 1160-1174
11. Errico M, Riccioni T, Iyer S, Pisano C, Acharya KR, Persico MG, De Falco S (2004) Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor. J Biol Chem 279: 43929-43939
12. Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M (2003) Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKCBeta. Bioorg Med Chem Lett 13: 1857-1859
13. Fine HA, Kim L, Royce C, Draper D, Haggarty I, Ellinzano H, Albert P, Kinney P, Musib L, Thornton D (2005) Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. Proc Am Soc Clin Oncol Abstract No.1504
14. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D (2005) The protein kinase Cbeta - selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65: 7462-7469
15. Hofmann J (2004) Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 4: 125-146
16. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354
17. Kawakami Y, Nishimoto H, Kitaura J, Maeda-Yamamoto M, Kato RM, Littman DR, Leitges M, Rawlings DJ, Kawakami T (2004) Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem 279: 47720-47725
18. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739
19. Keyes K, Cox K, Treadway P, Mann L, Shih C, Faul MM, Teicher BA (2002) An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res 62: 5597-5602
20. Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D, Chen YF, Iversen P, Teicher BA (2004) LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53: 133-140
21. Leong S, Camidge R, Eckhardt G, Basche M, Musib L, Darstein C, Thornton D, Britten C (2008) A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer. Anticancer Drugs 19: 77-84
22. Liu Y, Su W, Thompson EA, Leitges M, Murray NR, Fields AP (2004) Protein kinase CbetaII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J Biol Chem 279: 45556-45563
23. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385
24. Morgillo F, Lee HY (2005) Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 8: 298-310
25. Ono M, Kuwano M (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12: 7242-7251
26. Shojaei F, Ferrara N (2007) Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 87: 227-230
27. Tabatabai G, Frank B, Wick A, Lemke D, von Kürthy G, Obermüller U, Heckl S, Christ G, Weller M, Wick W (2007) Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 61: 153-161
28. Teicher BA, Menon K, Alvarez E, Shih C, Faul MM (2002) Antiangiogenic effects of a protein kinase C beta-selective small molecule. Cancer Chemother Pharmacol 49: 69-77
29. Tortora G, Ciardiello F, Gasparini G (2008) Combined targeting of EGFR and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol (in press) [E-pub ahead of print]
30. Tsai JC, Teng LJ, Chen CT, Hong TM, Goldman CK, Gillespie GY (2003) Protein kinase C mediates induced secretion of vascular endothelial growth factor by human glioma cells. Biochem Biophys Res Commun 309: 952-960
31. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61: 5090-5101
32. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL (1996) Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98: 2018-2026
33. Yan Liu WS, Thompson A, Leitges M, Murray NR, Fields AP (2004) Protein kinase C-βII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J Biol Chem 279: 45556-45563
34. Yoshiji H, Kuriyama S, Ways DK, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Tsujinoue H, Nakatani T, Shibuya M, Fukui H (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59: 4413-4418
35. Zhang J, Anastasiadis PZ, Liu Y, Thompson EA, Fields AP (2004) Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem 279: 22118-22123